๐Ÿ‡บ๐Ÿ‡ธ CSL and Alentis announce global partnership to develop and commercialise lixudebart for rare kidney and liver diseases

๐Ÿ‡บ๐Ÿ‡ธ

Alentis to receive US$355 million initial payment and up to US$1.2 billion in commercial milestones, with global profits shared MELBOURNE, Australia and BASEL, Switzerland, Oct. 4, 2026 /PRNewswire/ — CSL and Alentis Therapeutics today announced they have entered into an exclusive global…

Source: prnewswire

Country: United States